Home
Data
Calendar
Blog
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | NA | NA | 0.00 | 0.00 | NA | NA | NA | |
| Weighted Average Number Of Diluted Shares Outstanding | 26.06 | NA | 25.79 | 25.42 | 20.06 | NA | 380.76 | 337.75 | 244.37 | NA | 210.33 | 1.10 | 0.55 | NA | NA | NA | NA | |
| Weighted Average Number Of Shares Outstanding Basic | 26.06 | NA | 25.79 | 25.42 | 20.06 | NA | 380.76 | 337.75 | 244.37 | NA | 185.68 | 1.10 | 0.55 | NA | 0.00 | NA | NA | |
| Earnings Per Share Basic | -0.78 | -0.92 | -1.64 | -1.84 | -3.04 | -0.88 | -0.20 | -0.25 | -0.31 | 0.98 | 0.17 | -41.94 | -348.82 | 885682.00 | -456573.00 | NA | NA | |
| Earnings Per Share Diluted | -0.78 | -0.92 | -1.64 | -1.84 | -3.04 | -0.88 | -0.20 | -0.25 | -0.31 | 0.98 | 0.15 | -41.94 | -348.82 | 885682.00 | -456573.00 | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue From Contract With Customer Excluding Assessed Tax | 62.42 | 57.42 | 53.30 | 48.71 | 43.14 | 61.35 | 83.23 | 36.17 | 53.94 | 57.80 | 43.18 | 47.02 | 64.20 | 63.96 | 38.61 | 30.10 | 46.66 | |
| Revenues | 62.42 | 57.42 | 53.30 | 48.71 | 43.14 | 61.35 | 83.23 | 36.17 | 53.94 | 57.80 | 43.18 | 47.02 | 64.20 | 63.96 | 38.61 | 30.10 | 46.66 | |
| Cost Of Goods And Services Sold | 25.01 | 26.66 | 28.04 | 29.95 | 27.90 | 77.68 | 69.69 | 65.77 | 48.32 | 60.61 | 58.75 | 48.18 | 68.52 | 69.63 | 36.53 | 34.51 | 37.14 | |
| Gross Profit | 37.41 | 30.75 | 25.26 | 18.76 | 15.24 | -16.33 | 13.55 | -29.60 | 5.62 | -2.81 | -15.57 | -1.16 | -4.32 | -5.67 | 2.08 | -4.40 | 9.52 | |
| Research And Development Expense | 11.57 | 12.25 | 14.29 | 17.14 | 14.59 | 24.37 | 13.35 | 27.17 | 21.32 | 22.25 | 17.83 | 11.95 | 53.13 | 31.16 | 19.08 | 9.36 | 13.10 | |
| General And Administrative Expense | 22.45 | 26.63 | 26.10 | 37.34 | 43.69 | 40.65 | 51.86 | 68.03 | 42.78 | 57.95 | 33.23 | 12.87 | 102.04 | 61.12 | 24.34 | 8.12 | 7.16 | |
| Selling And Marketing Expense | 16.09 | 15.56 | 16.76 | 15.18 | 13.45 | 31.80 | 37.45 | 36.12 | 29.55 | 30.65 | 22.12 | 18.57 | 35.37 | 23.94 | 12.73 | 10.17 | 13.83 | |
| Operating Income Loss | -13.66 | -25.64 | -42.97 | -51.62 | -60.36 | -324.88 | -90.82 | -162.65 | -89.31 | -115.78 | -89.60 | -45.45 | -196.66 | -125.05 | -56.02 | -34.16 | -26.77 | |
| Interest Income Expense Net | -0.60 | -0.98 | 1.05 | NA | -0.04 | 0.33 | 0.19 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Interest Paid Net | 2.02 | 1.93 | 0.17 | 0.36 | 0.58 | 0.14 | 0.60 | 0.59 | 0.61 | 0.62 | 0.68 | 0.72 | 0.72 | -0.08 | NA | NA | NA | |
| Allocated Share Based Compensation Expense | -0.45 | -0.91 | 0.43 | 0.11 | 0.05 | 0.42 | 1.27 | 22.72 | 17.56 | 36.97 | 18.01 | -0.52 | 164.96 | 90.16 | 29.45 | NA | NA | |
| Income Tax Expense Benefit | -0.08 | -0.41 | -0.17 | -0.20 | -0.15 | 0.09 | -0.07 | -49.08 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Income Taxes Paid | 0.30 | 0.29 | 0.17 | 0.90 | 0.10 | 0.75 | 0.12 | 0.20 | 0.17 | 0.30 | NA | NA | NA | NA | NA | NA | NA | |
| Other Comprehensive Income Loss Net Of Tax | -0.13 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Net Income Loss | -20.24 | -25.77 | -42.29 | -46.72 | -60.99 | -308.76 | -77.58 | -85.74 | -76.90 | -40.19 | 31.39 | -46.16 | -58.47 | -125.68 | -56.62 | -32.05 | -26.99 | |
| Comprehensive Income Net Of Tax | -20.37 | NA | NA | -46.72 | -60.99 | -308.76 | -77.58 | -85.74 | -76.90 | -40.19 | 31.39 | -46.16 | -191.78 | -125.68 | -56.62 | -32.05 | -26.99 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 394.53 | 418.76 | 417.29 | 476.39 | 545.29 | 490.94 | 828.97 | 933.28 | 517.67 | 554.09 | 603.36 | 175.53 | 443.70 | 444.14 | NA | NA | NA | |
| Liabilities | 187.31 | 190.74 | 163.03 | 180.28 | 216.83 | 237.24 | 267.68 | 296.01 | 188.23 | 165.99 | 212.09 | 407.60 | 143.95 | 85.92 | NA | NA | NA | |
| Liabilities And Stockholders Equity | 394.53 | 418.76 | 417.29 | 476.39 | 545.29 | 490.94 | 828.97 | 933.28 | 517.67 | 554.09 | 603.36 | 175.53 | 443.70 | 444.14 | NA | NA | NA | |
| Stockholders Equity | 207.22 | 228.02 | 254.26 | 296.11 | 328.47 | 253.71 | 561.29 | 637.27 | 329.44 | 388.10 | 391.26 | -564.92 | 5.00 | 5.00 | 5.00 | -147.75 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets Current | 163.42 | 182.34 | 171.81 | 213.28 | 272.35 | 212.62 | 306.61 | 402.70 | 410.42 | 483.54 | 538.51 | 99.01 | 0.92 | 1.37 | NA | NA | NA | |
| Cash And Cash Equivalents At Carrying Value | 83.67 | 99.68 | 87.39 | 156.66 | 201.90 | 123.93 | 191.36 | 284.65 | 315.00 | 400.57 | 461.28 | 461.28 | 0.63 | 1.09 | 1.14 | NA | NA | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 84.66 | 100.67 | 88.29 | 157.56 | 214.94 | 138.30 | 205.73 | 299.02 | 315.90 | 401.47 | 462.18 | 462.18 | 69.48 | 118.96 | 139.68 | NA | NA | |
| Marketable Securities Current | 29.24 | 30.47 | 26.91 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Inventory Net | 11.62 | 8.78 | 9.35 | 11.53 | 12.33 | 13.66 | 44.17 | 41.60 | 36.32 | 33.46 | 31.17 | 29.13 | 32.97 | 24.96 | NA | NA | NA | |
| Prepaid Expense And Other Assets Current | 9.97 | 10.60 | 15.76 | 11.19 | 12.43 | 18.21 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Property Plant And Equipment Gross | NA | 78.93 | 139.72 | 143.88 | 156.04 | 152.99 | 155.70 | 153.79 | NA | 114.62 | NA | NA | NA | 93.21 | NA | NA | NA | |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | NA | 46.45 | 103.98 | 100.55 | 106.53 | 101.46 | 71.33 | 64.34 | NA | 51.91 | NA | NA | NA | 30.10 | NA | NA | NA | |
| Property Plant And Equipment Net | NA | 32.48 | 35.75 | 43.33 | 49.51 | 51.53 | 84.37 | 89.45 | NA | 62.72 | 60.33 | 62.10 | 64.63 | 63.11 | NA | NA | NA | |
| Intangible Assets Net Excluding Goodwill | 169.12 | 172.62 | 176.13 | 179.64 | 183.14 | 186.65 | 190.16 | 193.66 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Finite Lived Intangible Assets Net | 169.12 | 172.62 | 176.13 | 179.64 | 183.14 | 186.65 | 190.16 | 193.66 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other Assets Noncurrent | 4.38 | 4.41 | 6.06 | 5.56 | 6.16 | 6.49 | 7.97 | 7.87 | 6.95 | 6.93 | 3.61 | 3.60 | 3.60 | 3.60 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities Current | 50.73 | 58.82 | 68.37 | 84.37 | 119.03 | 144.30 | 162.33 | 204.61 | 100.64 | 101.28 | 71.37 | 72.61 | 1.49 | 0.10 | NA | NA | NA | |
| Long Term Debt Current | 0.80 | 0.50 | 0.20 | NA | NA | 4.75 | 0.35 | NA | NA | NA | NA | NA | NA | 1.77 | NA | NA | NA | |
| Accounts Payable Current | 9.48 | 10.24 | 15.37 | 25.01 | 36.92 | 46.02 | 40.12 | 53.30 | NA | 44.69 | 43.32 | 45.23 | 42.10 | 26.74 | NA | NA | NA | |
| Accounts Payable And Accrued Liabilities Current | 32.41 | 37.46 | 38.87 | 54.77 | 69.89 | 38.86 | 86.88 | 115.88 | NA | 64.80 | NA | NA | 1.49 | 0.10 | NA | NA | NA | |
| Accrued Liabilities Current | 11.29 | 12.15 | 13.32 | 16.75 | 27.57 | 38.86 | 26.15 | 23.01 | NA | 20.11 | NA | NA | NA | 11.85 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long Term Debt | 56.25 | 56.25 | 6.25 | 6.25 | 6.25 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | NA | NA | NA | NA | NA | NA | |
| Long Term Debt Noncurrent | 52.29 | 52.69 | 6.05 | 6.25 | 6.25 | 6.25 | 10.65 | 11.00 | 11.00 | 11.00 | 11.00 | 18.03 | 18.50 | 18.97 | NA | NA | NA | |
| Deferred Finance Costs Noncurrent Net | 3.16 | 3.06 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Deferred Income Tax Liabilities Net | 1.42 | 1.56 | 2.06 | 2.25 | 2.51 | 2.66 | 2.60 | 2.67 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other Liabilities Noncurrent | 20.84 | 14.73 | 22.66 | 22.41 | 22.11 | 22.00 | 20.20 | 0.50 | 0.50 | 3.48 | 21.70 | 21.91 | 22.53 | 22.85 | NA | NA | NA | |
| Operating Lease Liability Noncurrent | NA | 44.43 | NA | 45.83 | 45.82 | 44.47 | 45.13 | 45.48 | 39.65 | NA | NA | NA | NA | NA | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | 207.22 | 228.02 | 254.26 | 296.11 | 328.47 | 253.71 | 561.29 | 637.27 | 329.44 | 388.10 | 391.26 | -564.92 | 5.00 | 5.00 | 5.00 | -147.75 | NA | |
| Common Stock Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | NA | NA | 0.00 | 0.00 | NA | NA | NA | |
| Additional Paid In Capital | 1527.35 | 1527.78 | 1528.67 | 1528.24 | 1513.88 | 1378.09 | 1376.92 | 1375.32 | 981.76 | 963.52 | 926.25 | 1.48 | 103.38 | 44.91 | NA | NA | NA | |
| Retained Earnings Accumulated Deficit | -1320.43 | -1300.19 | -1274.41 | -1232.13 | -1185.41 | -1124.42 | -815.66 | -738.08 | -652.34 | -575.44 | -535.01 | -567.99 | -98.38 | -39.91 | NA | NA | NA | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0.29 | 0.42 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | -0.45 | -0.91 | 0.43 | 0.11 | 0.05 | 0.42 | 1.27 | 22.72 | 17.56 | 36.97 | 5.42 | NA | NA | NA | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -16.41 | -29.86 | -41.23 | -53.50 | -55.56 | -64.65 | -88.36 | -84.64 | -81.49 | -51.98 | -70.94 | -25.30 | -42.21 | -18.33 | NA | NA | NA | |
| Net Cash Provided By Used In Investing Activities | 0.84 | -4.86 | -27.13 | -11.27 | -0.46 | -2.84 | -4.28 | -130.30 | -3.91 | -7.69 | -3.62 | -4.48 | -4.99 | -11.50 | NA | NA | NA | |
| Net Cash Provided By Used In Financing Activities | -0.44 | 47.10 | -0.91 | 7.39 | 132.66 | 0.07 | -0.65 | 198.06 | -0.16 | -1.03 | 499.40 | -2.37 | -2.28 | 9.11 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -16.41 | -29.86 | -41.23 | -53.50 | -55.56 | -64.65 | -88.36 | -84.64 | -81.49 | -51.98 | -70.94 | -25.30 | -42.21 | -18.33 | NA | NA | NA | |
| Net Income Loss | -20.24 | -25.77 | -42.29 | -46.72 | -60.99 | -308.76 | -77.58 | -85.74 | -76.90 | -40.19 | 31.39 | -46.16 | -58.47 | -125.68 | -56.62 | -32.05 | -26.99 | |
| Depreciation Depletion And Amortization | 1.70 | 2.60 | 5.20 | 6.80 | 5.10 | 39.91 | 7.00 | 6.60 | 5.80 | 5.79 | 5.50 | 5.60 | 4.90 | 3.59 | 3.10 | NA | NA | |
| Increase Decrease In Other Operating Capital Net | 4.29 | 1.16 | NA | NA | 2.79 | -0.16 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Increase Decrease In Accounts Receivable | -4.22 | 0.46 | -0.55 | -0.45 | -9.72 | -0.04 | -3.13 | -13.49 | 11.13 | 5.25 | -3.31 | -8.77 | 1.30 | 7.45 | NA | NA | NA | |
| Increase Decrease In Inventories | 2.88 | -0.29 | -1.17 | 1.82 | -1.33 | -7.59 | 2.96 | -0.62 | 2.90 | 3.29 | 0.70 | -3.20 | 9.83 | 0.87 | NA | NA | NA | |
| Share Based Compensation | -0.45 | -0.91 | 0.43 | 0.11 | 0.05 | 0.42 | 1.27 | 22.72 | 17.56 | 36.97 | 18.01 | -0.52 | 164.96 | 90.16 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Investing Activities | 0.84 | -4.86 | -27.13 | -11.27 | -0.46 | -2.84 | -4.28 | -130.30 | -3.91 | -7.69 | -3.62 | -4.48 | -4.99 | -11.50 | NA | NA | NA | |
| Payments To Acquire Property Plant And Equipment | 0.44 | 2.38 | 0.11 | NA | NA | 2.17 | 2.24 | 1.37 | 1.38 | 5.06 | 1.02 | 1.25 | 2.08 | 6.78 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | -0.44 | 47.10 | -0.91 | 7.39 | 132.66 | 0.07 | -0.65 | 198.06 | -0.16 | -1.03 | 499.40 | -2.37 | -2.28 | 9.11 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 62.42 | 57.42 | 53.30 | 48.71 | 43.14 | 61.35 | 83.23 | 36.17 | 53.94 | 57.80 | 43.18 | 47.02 | 64.20 | 63.96 | 38.61 | 30.10 | 46.66 | |
| Operating | 62.42 | NA | NA | 48.71 | 43.14 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Operating, Gene Dx | 61.46 | NA | NA | NA | 40.69 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Operating, Legacy Sema4 | 0.96 | NA | NA | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Bio Reference Laboratories Inc, Related Party | 0.40 | 0.60 | 0.70 | NA | 0.70 | 0.70 | 0.60 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Product And Service Other | 1.32 | 2.20 | 1.35 | 2.07 | 1.29 | 2.00 | 1.74 | 2.17 | 1.45 | 1.67 | 1.77 | 2.21 | 1.44 | 2.37 | 0.71 | NA | NA | |
| Diagnostic Test | 61.10 | 55.21 | 51.95 | 46.63 | 41.85 | 59.34 | 81.49 | 34.00 | 52.49 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Institutional Customers | 16.67 | 11.97 | 15.72 | 15.75 | 16.06 | 15.73 | 15.24 | 11.12 | 4.03 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay | 0.59 | 0.43 | 0.46 | 0.31 | 0.46 | 3.24 | 1.85 | 1.49 | 1.00 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance | 43.84 | 42.81 | 35.77 | 30.57 | 25.33 | 40.37 | 64.39 | 21.40 | 47.46 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Related Party | 0.60 | 0.74 | 0.81 | 0.80 | 0.80 | 0.82 | 0.81 | 0.41 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Product And Service Other, Gene Dx | 1.32 | 2.20 | 1.35 | NA | 1.29 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Gene Dx | 60.14 | 55.90 | 49.00 | NA | 39.40 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Legacy Sema4 | 0.96 | -0.69 | 2.95 | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Institutional Customers, Gene Dx | 16.67 | 11.97 | 15.72 | NA | 16.06 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay, Gene Dx | 0.59 | 0.47 | 0.46 | NA | 0.47 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay, Legacy Sema4 | NA | -0.04 | 0.00 | NA | -0.01 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance, Gene Dx | 42.88 | 43.46 | 32.83 | NA | 22.88 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance, Legacy Sema4 | 0.96 | -0.65 | 2.95 | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Related Party | NA | 0.74 | 0.81 | 0.70 | NA | 0.87 | 0.96 | 0.30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Gene Dx | 61.46 | 58.11 | 50.35 | NA | 40.69 | 50.52 | 45.58 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Legacy Sema4 | 0.96 | -0.69 | 2.95 | 3.48 | 2.45 | 10.83 | 37.65 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Revenue From Contract With Customer Excluding Assessed Tax | 62.42 | 57.42 | 53.30 | 48.71 | 43.14 | 61.35 | 83.23 | 36.17 | 53.94 | 57.80 | 43.18 | 47.02 | 64.20 | 63.96 | 38.61 | 30.10 | 46.66 | |
| Operating | 62.42 | NA | NA | 48.71 | 43.14 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Operating, Gene Dx | 61.46 | NA | NA | NA | 40.69 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Operating, Legacy Sema4 | 0.96 | NA | NA | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Bio Reference Laboratories Inc, Related Party | 0.40 | 0.60 | 0.70 | NA | 0.70 | 0.70 | 0.60 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Product And Service Other | 1.32 | 2.20 | 1.35 | 2.07 | 1.29 | 2.00 | 1.74 | 2.17 | 1.45 | 1.67 | 1.77 | 2.21 | 1.44 | 2.37 | 0.71 | NA | NA | |
| Diagnostic Test | 61.10 | 55.21 | 51.95 | 46.63 | 41.85 | 59.34 | 81.49 | 34.00 | 52.49 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Institutional Customers | 16.67 | 11.97 | 15.72 | 15.75 | 16.06 | 15.73 | 15.24 | 11.12 | 4.03 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay | 0.59 | 0.43 | 0.46 | 0.31 | 0.46 | 3.24 | 1.85 | 1.49 | 1.00 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance | 43.84 | 42.81 | 35.77 | 30.57 | 25.33 | 40.37 | 64.39 | 21.40 | 47.46 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Related Party | 0.60 | 0.74 | 0.81 | 0.80 | 0.80 | 0.82 | 0.81 | 0.41 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Product And Service Other, Gene Dx | 1.32 | 2.20 | 1.35 | NA | 1.29 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Gene Dx | 60.14 | 55.90 | 49.00 | NA | 39.40 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test, Legacy Sema4 | 0.96 | -0.69 | 2.95 | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Institutional Customers, Gene Dx | 16.67 | 11.97 | 15.72 | NA | 16.06 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay, Gene Dx | 0.59 | 0.47 | 0.46 | NA | 0.47 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Self Pay, Legacy Sema4 | NA | -0.04 | 0.00 | NA | -0.01 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance, Gene Dx | 42.88 | 43.46 | 32.83 | NA | 22.88 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Diagnostic Test Third Party Insurance, Legacy Sema4 | 0.96 | -0.65 | 2.95 | 3.48 | 2.45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Related Party | NA | 0.74 | 0.81 | 0.70 | NA | 0.87 | 0.96 | 0.30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Gene Dx | 61.46 | 58.11 | 50.35 | NA | 40.69 | 50.52 | 45.58 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Legacy Sema4 | 0.96 | -0.69 | 2.95 | 3.48 | 2.45 | 10.83 | 37.65 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
